CSIMarket Company Name, Ticker, Industry, else..
 
Agios Pharmaceuticals Inc   (NASDAQ: AGIO)
 
Price: $33.1000 $-0.03 -0.091%
Day's High: $33.5 Week Perf: -1.72 %
Day's Low: $ 32.92 30 Day Perf: 3.6 %
Volume (M): 480,160 52 Wk High: $ 46.00
Volume (M$): $ 0 52 Wk Avg: $32.36
Open: $33.13 52 Wk Low: $22.24



 Market Capitalization (Millions $) 1,946
 Shares Outstanding (Millions) 59
 Employees 540
 Revenues (TTM) (Millions $) 66
 Net Income (TTM) (Millions $) -423
 Cash Flow (TTM) (Millions $) 35
 Capital Exp. (TTM) (Millions $) 4

Business Description


Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the development of therapies for cancer and rare genetic diseases. The company utilizes its expertise in cellular metabolism to discover and develop potential treatments. Agios is known for its innovative approaches to targeting specific metabolic pathways that play a critical role in disease progression. The company's pipeline includes both small molecule and antibody-based therapies, with several candidates in various stages of clinical development. Agios Pharmaceuticals aims to deliver breakthrough treatments that can significantly improve the lives of patients in need.


   Company Address: 88 Sidney Street Cambridge 2139 MA
   Company Phone Number: 649-8600   Stock Exchange / Ticker: NASDAQ AGIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        0.36% 
PFE        1.75% 
REGN        4.22% 
TEVA   -0.22%    
VRTX        0.82% 
VTRS        3.3% 
• View Complete Report
   



Clinical Study

Breaking Boundaries in Blood Disorder Treatment Mitapivats Promising Path in Thalassemia Care,

Published Mon, Oct 20 2025 10:14 AM UTC

: This article discusses recent advancements in treatment options for thalassemia, with a focus on the positive progress made with PYRUKYND (mitapivat). Agios Pharmaceuticals has reported significant milestones, including a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) and the FDA s acceptance of a supplemental New Drug Application (sNDA) ...
Business Update

Agios Pharmaceuticals Expands European Footprint with Avanzanite Partnership for PYRUKYND in Rare Blood Disorders

Published Wed, Jun 11 2025 9:40 AM UTC

In a significant move to enhance its market presence and address the needs of patients with rare blood clotting disorders, Agios Pharmaceuticals Inc. (NASDAQ: AGIO) announced a strategic partnership with Avanzanite. This collaboration aims to facilitate the introduction of PYRUKYND, a key therapeutic product, across Europe. The initiative not only solidifies Agios s commitme...
Business Update

Strategic Synergy Avanzanite and Agios Foster Pan-European Launch of PYRUKYND to Revolutionize Rare Blood Disorder Tr...

Published Mon, Jun 9 2025 4:57 PM UTC

Expanding Horizons in Rare Blood Disorders: Avanzanite and Agios Pharmaceuticals Forge a Strategic Alliance for PYRUKYND Launch The landscape of rare blood disorder treatment is experiencing a significant shift with the recent announcement of a strategic partnership between Avanzanite Bioscience B.V. and Agios Pharmaceuticals, Inc. This collaboration sets the stage for the ...
Management Changes

“Agios Pharmaceuticals Sees Strong Q4 Performance and Advances Mitapivat to Transform Thalassemia Treatment”,

Published Thu, Feb 13 2025 11:31 AM UTC

Agios Pharmaceuticals Reports Q4 and Full Year 2024 Financial Results, Advances Mitapivat for Thalassemia TreatmentAgios Pharmaceuticals Inc. a biopharmaceutical company focused on discovering and developing innovative therapies for rare diseases, has announced its financial results for the fourth quarter and full year of 2024. The report highlights significant advancements ...
Clinical Study

Agios Pharmaceuticals Reports Positive Phase 3 ACTIVATE-Kids Study Results for Mitapivat in Pediatric Patients with P...

Published Thu, Feb 13 2025 11:49 AM UTC

Agios Pharmaceuticals Inc. has announced promising results from the Phase 3 ACTIVATE-Kids study evaluating Mitapivat, a novel oral therapy, in children diagnosed with Pyruvate Kinase (PK) deficiency who are not regularly transfused. This study marks a significant milestone, being the first to demonstrate the efficacy of an oral therapeutic option for this pediatric populatio...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 29.46
Price to Sales (Expected) -
Price to Book 1.75
PEG (TTM) -

Financial Strength Current
Quick Ratio 18.41
Working Capital Ratio 20.85
Leverage Ratio (MRQ) 0.07
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -7.26 $
Revenues (TTM) 1.12 $
Cash Flow (TTM) 0.59 $
Cash 12.54 $
Book Value 18.87 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 122,311
Net Income per Employee (TTM) -782,598
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) 0.2
Asset Turnover Ratio (TTM) 0.05

Profitability Ratios Current
Gross Margin (MRQ) 93.64 %
Operating Margin (MRQ) -530.34 %
Net Margin (MRQ) -477.74 %
Net Cash Flow Margin (MRQ) 117.95 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Agios Pharmaceuticals Inc's Segments
Product revenue net    100 % of total Revenue
Product revenue net United States    90.87 % of total Revenue
Product revenue net Rest of world    9.13 % of total Revenue
Product revenue net Reportable United States    90.87 % of total Revenue
Product revenue net Reportable Rest of world    9.13 % of total Revenue

  Agios Pharmaceuticals Inc Outlook

On May 2 2024 the Agios Pharmaceuticals Inc provided following guidance

Agios Pharmaceuticals Inc. has reported its busi...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.